PuSH - Publication Server of Helmholtz Zentrum München

Aberle, J.* ; Lautenbach, A.* ; Meyhöfer, S.* ; Menzen, M.* ; Selig, L.* ; Mai, K.* ; Blüher, M. ; Terkamp, C.*

Obesity and Diabetes.

Exp. Clin. Endocrinol. Diabet., DOI: 10.1055/a-2766-3375 (2026)
DOI
Open Access Green as soon as Postprint is submitted to ZB.
Weight reduction strategies are part of the basic therapy for people with obesity or type 2 diabetes. People with type 2 diabetes should be motivated to eat a healthy and balanced diet and increase physical activity. Targeted weight reduction is also an escalation step in therapy for patients with type 2 diabetes. When choosing drug therapy for type 2 diabetes, preference should be given to active ingredients (metformin, GLP-1 receptor agonists, GIP/GLP-1 receptor co-agonist, SGLT-2 inhibitors) that enable weight reduction. Since weight reduction for people with obesity or type 2 diabetes is difficult to achieve through conservative therapy strategies, in recent years, metabolic surgery has become the therapy alternative for patients with type 2 diabetes and a BMI > 35 kg/m2. Compared to conservative type 2 diabetes therapy, metabolic surgery is significantly more effective in terms of weight reduction, long-term weight stability and blood glucose reduction, but is also associated with higher acute and long-term risks.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Guideline
Keywords Life-style Intervention; Weight-loss; Bariatric Surgery; Type-2; Individuals; Association; Prevention; Management; Overweight; Safety
ISSN (print) / ISBN 0947-7349
e-ISSN 1439-3646
Journal Experimental and Clinical Endocrinology & Diabetes
Publisher Thieme
Publishing Place Stuttgart
Reviewing status Peer reviewed
Institute(s) Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)